Source of candidaemia [n (%)]
|
Definitive CVC-related
|
34 (29.1%)
|
27 (29.0%)
|
7 (29.2%)
|
0.990
|
Intra-abdominal
|
24 (20.5%)
|
18 (19.4%)
|
6 (25.0%)
|
0.744
|
Primary
|
22 (18.8%)
|
15 (16.1%)
|
7 (29.2%)
|
0.244
|
Lower respiratory tract
|
12 (10.3%)
|
11 (11.8%)
|
1 (4.2%)
|
0.468
|
Urinary tract infection
|
7 (6.0%)
|
6 (6.5%)
|
1 (4.2%)
|
> 0.999
|
Gastrointestinal tract
|
6 (5.1%)
|
6 (6.5%)
|
0 (0.0%)
|
0.344
|
Skin and Soft tissue
|
5 (4.3%)
|
4 (4.3%)
|
1 (4.2%)
|
> 0.999
|
Meningitis
|
3 (2.6%)
|
2 (2.2%)
|
1 (4.2%)
|
0.501
|
Endocardium
|
2 (1.7%)
|
2 (2.2%)
|
0 (0.0%)
|
> 0.999
|
Osteoarthritis
|
1 (0.9%)
|
1 (1.1%)
|
0 (0.0%)
|
> 0.999
|
Source control [n (%)]
|
Removal of contaminated lines a
|
40 (34.2%)
|
27 (29.0%)
|
13 (54.2%)
|
0.021
|
Draining of fungal collection
|
19 (16.2%)
|
14 (15.1%)
|
5 (20.8%)
|
0.708
|
Days of prior antibiotic exposure (IQR)
|
11.0 (3.0,22.0)
|
8.0 (1.0,20.5)
|
17.0 (10.3,28.8)
|
0.007
|
Prior antibiotic exposure b [n (%)]
|
93 (79.5%)
|
69 (74.2%)
|
24 (100.0%)
|
0.012
|
Cephalosporins
|
33 (28.2%)
|
25 (26.9%)
|
8 (33.3%)
|
0.531
|
Carbapenems
|
49 (41.9%)
|
41 (44.1%)
|
8 (33.3%)
|
0.341
|
Penicillins
|
25 (21.4%)
|
19 (20.4%)
|
6 (25.0%)
|
0.626
|
Quinolones
|
4 (3.4%)
|
4 (4.3%)
|
0 (0.0%)
|
0.580
|
Initial antifungal agent [n (%)]
|
Fluconazole
|
40 (34.2%)
|
32 (34.4%)
|
8 (33.3%)
|
0.921
|
Echinocandin
|
46 (39.3%)
|
36 (38.7%)
|
10 (41.7%)
|
0.791
|
Voriconazole
|
11 (9.4%)
|
9 (9.7%)
|
2 (8.3%)
|
> 0.999
|
Prior antifungal exposure [n (%)]
|
10 (8.5%)
|
6 (6.4%)
|
4 (16.7%)
|
0.235
|
Appropriate Antifungal therapy c [n (%)]
|
43 (36.8%)
|
35 (37.6%)
|
8 (33.3%)
|
0.697
|
Delay in initiation of empiric antifungal treatment d [n (%)]
|
100 (85.5%)
|
82 (88.2%)
|
18 (75.0%)
|
0.103
|